Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of sustained interferon alfa 2b (inf) therapy of relapsing hepatitis c (hcv) patients using infradure biopump

Conditions: Hepatitis C

Summary: patients who completed the conventional treatment against hcv and relapsed (the virus appeared again in their blood) have no effective therapy.

the rational behind the proposed study is that most patients can not tolerate the prolonged ifn injections because the side effects. the new proposed treatments allows continous low doses of ifn to be secreted by the patients himself using his own skin in which the dermo fibroblasts are enriched by a human gene of erythropoietin. the "biopump" continues to secret the ifn for several months avoiding the spikes of ifn in the plasma which are beleived to cause the undesired effects. patients will be able to complete a long treatment with low ifn dose and ribavirin hoping to induce prolonged remission and cure

Eligibility criteria:
inclusion criteria: * signed patient consent form * chronic hcv patients in relapse following conventional treatment regimen (inf+ribavirine) with detectable plasma level of hcv rna * hepatitis b and human immunodeficiency virus negative at screening visit * able and willing to follow contraception requirements * screening laboratory values, test, and physical exam within acceptable range exclusion criteria: * current enrollment in another investigational device or drug study * anticipated inability to complete all clinic visits and comply with study procedures * history of, or any current medical condition, which could impact the safety of the subject during the study * autoimmune hepatitis, suspected hepatocellular carcinoma, decompensated liver disease, or other known liver disease other than hcv * alcoholism or substance abuse with \<6 documented months of sobriety * known allergy or sensitivity to interferons or ribavirin * any other condition that, in the opinion of the investigator, would make the subject unsuitable for enrollment or could interfere with the subject participating in and completing the study
role of cbc parameters in early diagnosis of pediatric pneumonia

Conditions: Pediatric Infectious Disease

Summary: detection of the role of complete blood count (cbc) parameters in early diagnosis of pediatric pneumonia -testing the ability of complete blood count (cbc) parameters (n/l ratio, plt /mpv ratio, mpv and other parameters) to differentiate between viral and bacterial pneumonia.

pneumonia is the leading cause of hospitalizations and death among children with nearly 120 million new cases and one million deaths every year. * viruses are the main cause of pneumonia in infants and toddlers between 30 days and 2 years old. * children 2 to 5 years old, respiratory viruses are also common with the rise of cases related to s. pneumoniae and h. influenzae type b and other bacterial organisms. viral pneumonia caused by , respiratory syncytial virus, which are the most common cause of community- acquired pneumonia in children younger than 5 years. streptococcus pneumoniae is the most common bacterial cause across all age groups. other important bacterial causes in children younger than 5 years include hemophilus influenzae, streptococcus pyogenes, staphylococcus aureus, and moraxella catarrhalis. parapneumonic effusion/empyema (ppe/ep), necrosis of lung parenchyma (nc), and lung abscess (ab), are serious complication of pediatric pneumonia. because of these serious complications, early diagnosis of the causative organism is very important to start the proper treatment and avoid these serious complications. complete blood picture (cbc) is one of the most important preliminary routine investigations for diagnosis and monitoring of infection. recently, cbc parameters, especially total leucocyte count (tlc), anc, and platelet count all showed significant associations with neonatal sepsis. besides, the tlc,absolute neutrophils count (anc), and platelet counts had good sensitivity and specificity in diagnosing neonatal sepsis another study have assessed the utility of c-reactive protein (crp), white cell count (wcc), neutrophil/lymphocyte ratio (n/l), platelets/ mean platelets volume ratio (plt/mpv ratio), mean platelets volume (mpv), monocyte distribution width (mdw) and many other cbc ratios to differentiate probable bacterial infections from non-bacterial infections and also assessed the severity of illness. - in this study, we are going to test the role of complete blood picture (cbc) parameters and ratios as an early detection tool of bacterial and viral pneumonia. this might have a role in early prediction and diagnosis of the causative organism. which in turn leads to rapid intervention, and better prognosis.

Eligibility criteria:
inclusion criteria: - newly suspected cases of pneumonia from age o 1 month to 5 years in 2 age groups exclusion criteria: * age group \>5 years * already diagnosed patient who is under treatment
vte prophylaxis guidelines in hospitalized elders

Conditions: Venous Thromboembolism

Summary: guideline directed use of pharmacologic venous thromboembolism (vte) prophylaxis emphasizes mobility evaluation. mobility is a key component of risk stratification. poor mobility evaluation by providers may be a significant barrier to appropriate use of vte prophylaxis. the investigators aim is to propose to determine whether level of mobility during hospitalization is being used to influence use and duration of vte prophylaxis among medically ill hospitalized elders. to achieve this aim, the investigator will collect prospective observational data to objectively measure inpatient mobility using patient mounted accelerometers during patient hospital stays. the investigator's goal is to improve the appropriateness of use of vte prophylaxis among those in which the risks of harm may outweigh the benefit. results from this study will provide important insights about use of risk assessment, and the relationship between patient mobility and vte prophylaxis. these results are critical to understanding how to take the next steps toward improving the appropriate use and safety of anticoagulants in hospitalized older adults. information from this study could be used in future proposals to study interventions to ultimately improve hospital practice in the care of older adults.


Eligibility criteria:
inclusion criteria: 1. age of 60 or older 2. admitted to general medicine at duke university exclusion criteria: 1. clear contraindications to pharmacologic vte prophylaxis 2. receiving surgery during their index hospital stay 3. on observation admission status 4. on negative pressure room respiratory isolation 5. wrist site is not available, i.e. wearing bilateral wrist ivs, skin breakdown at the time of screening 6. ankle site is not available, i.e. patients with leg ulcer at the time of screening 7. lacking decision-making ability (such as from severe cognitive impairment) and no lar available 8. non-english speakers
study to evaluate the inflammatory cells activity in patients with persistent asthma treated with montelukast (0476-403)(completed)

Conditions: Asthma

Summary: verify if the quantitative parameters of the eosinophils activation and phagocyte system function show a predictive value for clinical response and prognostic in patients with persistent asthma treated with montelukast


Eligibility criteria:
inclusion criteria: patients between 2-18 years with persistent asthma exclusion criteria: patients \> 18 years old and \< 2 years old
pipt in adsm with msd

Conditions: Chronic Pain; Musculoskeletal Diseases or Conditions

Summary: the study objective is to establish feasibility of implementing a psychologically informed rehabilitation strategy while concurrently assessing its' effectiveness in active duty service members (adsm) with musculoskeletal disorders (msd) seeking care in a us navy shore-based healthcare setting. this intervention is intended to improve the management of chronic pain in order to optimize adsm function. the study team is proposing an observational prospective comparative cohort study. this study tests an implementation/strategy while observing/gathering information on the clinical intervention and related outcomes.


Eligibility criteria:
inclusion criteria: * adsm (at baseline; separation from the military post-treatment will not be grounds for exclusion) * patients presenting to an nmcp or a branch clinic physical therapy department * patients who have only receive their evaluation appointment for their primary complaint * patients prescribing for a primary complaint of a msd (the following icd-10 codes will be included: m13, m14.8, m15-19, m21-25, m40-43, m46-48, m50-54, m60-71, m73, m75-77) exclusion criteria: * patients not eligible to receive outpatient physical therapy * patients receiving fewer than four treatment sessions of physical therapy * patients who are pregnant * patients receiving physical therapy for acute post-surgical recovery * patients scheduled for or subject to a physical evaluation board (peb) at baseline * coast guard

Keywords: psychologically informed physical therapy (pipt)
effect of qigong therapy in patients with advanced lung and gastrointestinal cancer undergoing chemotherapy

Conditions: Carcinoma, Non-Small-Cell Lung; Cancer of the Gastrointestinal Tract

Summary: cancer patients face a number of symptoms related to treatment or disease which may impair quality of life, such as decreased functional capacity, fatigue, nausea an vomiting, distress, depression and unmet psychological needs. due to this array of symptoms, cancer patients often seek supportive complementary and alternative medicine, which many patients use along with conventional treatments. qigong, a type traditional chinese medicine, is a mind-body exercise that combines meditation, slow physical movements, and controlled breathing. the investigators hypothesise that qigong therapy is better in the reduction of anxiety and depression levels and the improvement of quality of life in patients with lung and gastrointestinal (gi) cancer who are eligible for anti-cancer treatment, when compared to standard exercise training.

as per summary above

Eligibility criteria:
inclusion criteria: 1. a pathologically (histological or cytological) confirmed clinical diagnosis of non-small cell lung cancer (nsclc) or gi cancer 2. stage 3 or 4 disease and eligible for anti-cancer treatment 3. performance status (ps) of 0 - 2 as determined by the eastern cooperative oncology group-performance status 4. life expectancy estimated at \> 4 months 5. age 18 years or older 6. willing and able to provide informed consent 7. must be approved for participation by the oncology treatment team 8. able to communicate in french or english exclusion criteria: 1. contraindication to exercise as determined by the oncology treatment team 2. severe cardiac or neuro-muscular/skeletal disease 3. engaging in interventions to address anxiety or depressive symptoms 4. brain metastases 5. active psychiatric conditions 6. pregnant or breast-feeding mothers

Keywords: qigong complementary medicine exercise traditional chinese medicine meditation standard exercise chemotherapy advanced cancer quality of life functional assessment of cancer therapy hospital anxiety and depression scale anxiety depression cancer nutrition-rehabilitation program edmonton symptom assessment scale simmonds functional assessment
tacrolimus, sirolimus and ustekinumab vs. tacrolimus and sirolimus for the prevention of acute graft-versus-host disease

Conditions: Graft vs. Host Disease

Summary: to determine whether treatment with ustekinumab will alter the ratio of t regulatory cell (treg)/total cluster of differentiation 4 (cd4)+ cells in peripheral blood at day 30 post-hematopoietic cell transplantation (hct).

this is a comparative study to assess the biologic and clinical activity of the agent ustekinumab when given in concert with our established regimen of sir/tac. patients will be randomly assigned between the standard regimen of tacrolimus/sirolimus (tac/sir + placebo) vs. the investigational regimen of tacrolimus/sirolimus/ustekinumab (tac/sir/u) in a 1:1 scheme.

Eligibility criteria:
inclusion criteria: * hematologic disorder requiring allogeneic hematopoietic cell transplantation * adequate vital organ function: * left ventricular ejection fraction (lvef) \>/= 45% by multigated acquisition (muga) scan * fev1, fvc, and diffusing lung capacity oxygenation (dlco) \>/= 50% of predicted values on pulmonary function tests * transaminases (ast, alt) \< 3 times upper limit of normal values * creatinine clearance \>/= 50 cc/min. * performance status: karnofsky performance status score \>/= 60%. exclusion criteria: * active infection not controlled with appropriate antimicrobial therapy * hiv, hepatitis b, or hepatitis c infection * sorror's co-morbidity factors with total score \> 3 * important modification to co-morbidity index calculation: dlco will not be included in assessment of pulmonary risk, excepting those with dlco \< 50%, who will merit a score of 3 and thereby be excluded from the trial. * anti-thymocyte globulin (atg) as part of the conditioning regimen * cyclophosphamide as part of the conditioning regimens

Keywords: acute graft vs. host disease (agvhd) graft vs. host disease (gvhd)
removal of ligand-bound iron during intravenous (iv) iron administration in hemodialysis (hd)

Conditions: Hemodialysis Patients

Summary: the study's hypothesis is that hd with large pore dialyzers remove to the dialysate iron which is bound to potentially dialyzable ligands, after it's release from intravenous iron compound administered during hemodialysis.

most hemodialysis(hd) patients receive during hd intravenous iron compounds, which are composed of an iron core and a sugar polymer shell. a small percentage of iron from the iron compound is released to the plasma, and may be associated with increased oxidative stress and protein oxidation. the study's hypothesis is that hd with large pore dialyzers may remove to the dialysate iron which is bound to potentially dialyzable ligands, after it's release from intravenous iron compound administered during hemodialysis. ligand-bound iron removal is also hypothesized to be affected by dialysate calcium and bicarbonate concentrations, which may affect iron-ligand binding. study specific aims are: to evaluate 1. iron removal assessing dialysate iron levels. 2. effect of iron removal and it's associated experimental conditions on patient status, assessing plasma aopp levels and inflammation related parameters study include 3 parts 1. comparing large to small pore dialyzers (to achieve baseline uniform conditions, patients will be on uniform dialysate bicarbonate and calcium concentrations of 33 meq/l and 3 meq/l,respectively, using large pore dialyzers during this part, besides the 2 hd sessions evaluating low pore dialyzers) and after few week break using large pore dialyzers to compare 2. low to high dialysate bicarbonate concentration (using uniform dialysate calcium concentrations of 3 meq/l) and after few week break 3. low to high dialysate calcium concentrations concentration (using uniform dialysate bicarbonate of 33 meq/l) in each part, patients will be first evaluated in hd without iv iron administration, which will serve as a control for evaluation after a week in hd with iv iron administration. in each part, patients will be randomized to start either with one of the 2 experimental conditions, and after 1 week without evaluation will cross-over to the other experimental condition. patients may participate in 1,2 or the 3 parts of study depending on their will and condition.

Eligibility criteria:
inclusion criteria: * chronic hemodialysis patients exclusion criteria: * acute disease (infection, thrombosis, ischemia, bleeding) hepatitis b, hepatitis c or hiv * intravenous iron administration or packed red cell transfusion in the last 3 weeks prior to the study * refusal to comply with limitations in fat containing food during hd with plasma sampling for aopp evaluation

Keywords: hemodialysis iron inflammation atomic absorption dialysate advanced oxidation protein products large pore dialysate bicarbonate calcium citrate ligand
using vitamin d to reduce oral mucosal inflammation in chemotherapy patients with oral squamous cell carcinoma

Conditions: Oral Squamous Cell Carcinoma; Oral Mucositis

Summary: oral squamous cell carcinoma is the most common malignant tumor of the oral and maxillofacial region. currently, surgery is the main method of comprehensive treatment. tpf (paclitaxel, cisplatin, and fluorouracil) chemotherapy regimen is one of the important methods for the treatment of oral squamous cell carcinoma. adjuvant chemotherapy before and after surgery can significantly improve the therapeutic effect of oral cancer patients. oral mucositis (om) is a common side effect during chemotherapy, which seriously affects the quality of life of chemotherapy patients and may lead to the termination of chemotherapy. prevention and treatment of oral mucositis is still an urgent clinical problem. investigators' previous studies have found that vitamin d can significantly inhibit the proliferation, migration, invasion and metastasis of oral squamous cell carcinoma cells, and vitamin d can protect normal oral mucosal tissue by inhibiting pyroptosis caused by platinum-based chemotherapy drugs. based on the previous basic research, this project intends to conduct a single-center, prospective, clinical randomized controlled study on the clinical efficacy of vitamin d in reducing oral mucosal inflammation in patients with oral squamous cell carcinoma undergoing tpf chemotherapy, in order to provide evidence-based medical evidence for the clinical use of vitamin d in reducing oral mucosal inflammation in patients with oral cancer chemotherapy. the results of this study are expected to serve as guidelines to guide clinical practice.


Eligibility criteria:
inclusion criteria: 1. patients aged 20-70 years 2. patients with pathologically diagnosed oral squamous cell carcinoma who need tpf-based chemotherapy regimens, and whose expected survival time is greater than 6 months 3. patients whose serum 25-hydroxyvitamin d level was vitamin d deficiency (\<30nmol/l) and adequate (30-50nmol/l) before chemotherapy 4. patients and their families agree to participate in this trial and sign an informed consent form 5. no cognitive impairment exclusion criteria: 1. people with oral ulcers or other oral mucosal diseases (such as: oral mucosal pemphigus, etc.) at the beginning of the study 2. patients who are allergic to alfacalcidol drops 3. patients with severe cardiac insufficiency, liver and kidney insufficiency, and systemic infectious diseases 4. pregnant women (judged by hcg test) and lactating patients 5. participating in other clinical trials during the study 6. those who do not understand or cooperate with clinical trials 7. patients with hypervitaminosis d, hypercalcemia, hyperphosphatemia and renal rickets
acute changes in bioimpedance during cardiac resynchronization therapy

Conditions: Heart Failure, Systolic

Summary: this study aims at optimizing measured parameters to reflect underlying pathology in dyssynchronous hearts. this is an experimental study in patients were bioimpedance measurements are performed during implantation.

patients who are eligible for implantation af a cardiac resynchronization therapy device according to european society of cardiology guidelines are included. measurements are performed on implanted leads and stored for post processing. the study entry ends for each patient with completion of the implantation procedure.

Eligibility criteria:
- indication for cardiac resynchronization therapy or upgrade of exciting device according to the current european society of cardiology guidelines.
guangzhou outdoor activity longitudinal study

Conditions: Myopia

Summary: the purpose of this study is to assess whether outdoor activities are effective in preventing the development and progression of juvenile-onset myopia in chinese children.

1. to determine if increased engagement in outdoor activities reduces the development and progression of myopia in chinese school children. 2. to identify the risk factors associated with the development and progression of juvenile-onset myopia. 3. to characterize the interaction between refractive error and education.

Eligibility criteria:
inclusion criteria: * all the students in grade 1 exclusion criteria: * no
offset mechanisms in evaluation of lumbar medial branch blocks

Conditions: Pain, Chronic; Facet Joint Pain; Pain, Procedural; Analgesia

Summary: this study examines the relationship between central nervous system (cns) mechanisms of pain inhibition and the pain relief that occurs following a lumbar medial branch block (mbb).

this study examines the relationship between central nervous system (cns) mechanisms of pain inhibition and the pain relief that occurs following a commonly-performed nerve block used to diagnose and treat chronic low back pain. patients scheduled for lumbar medial branch blocks as part of routine clinical care will arrive to clinic prior to the block for quantitative sensory testing procedures that measure cns pain modulation. patients will then undergo treatment as usual with their block, subsequently reporting low back pain intensity in a pain diary.

Eligibility criteria:
inclusion criteria: * scheduled for lumbar mbb in upmc pain management clinics * age \> 18 years old * predominantly axial chronic low back pain at least 3 months on a daily basis * must meet the minimum criteria for cognitive function using the promis 2-item cognitive screener (\>3) * low back pain intensity of \> 3/10 * willing and able to receive study-related phone calls exclusion criteria: * history of spine surgery at the level of the lumbar mbb * active worker's compensation or litigation claims * new pain and/or psychiatric treatments within 2 weeks of enrollment * not fluent in english and/or not able to complete the questionnaires * any clinically unstable systemic illness that is judged to interfere with the study

Keywords: lumbar medial branch block offset analgesia onset hyperalgesia qst quantitative sensory testing
physiological patterns of coronary artery disease

Conditions: Coronary Artery Disease

Summary: registry of patients undergoing invasive fractional flow reserve measurement using a motorized device.

a prospective registry of patients undergoing clinically indicated coronary angiography with fractional flow reserve evaluation for vessels with intermediate coronary lesions defined as visual diameter stenosis between 30% and 70%. a motorized fractional flow reservepullback evaluation will be performed at the discretion of the operators. the objective of the present study is to describe the physiological patterns of coronary artery disease using motorized coronary pressure pullbacks during continuous hyperemia in patients with stable coronary artery disease.

Eligibility criteria:
inclusion criteria: * stable coronary artery disease exclusion criteria: * acute coronary syndromes * previous coronary artery bypass grafting * significant valvular disease * severe obstructive pulmonary disease or asthma bronchial * severe tortuosity or severe calcification